















CTIS ACHIEVEMENTS

We're proud of our achievements and these accolades have led us to be respected by our peers and competitors and trusted by our clients. Our clients' trust is one of our most valued assets, and our most important recognition comes from serving our clients and knowing that we are a partner in growing their businesses. Our ongoing commitment to excellence stems from our shared desire to help clients accomplish their goals.

ACHIEVEMENTS	
	CTIS was recognized for seven consecutive years as a member of Deloitte's Fast 50 growing technology companies in Maryland. The awards are made based on the last five years of a company's growth. CTIS has achieved an annual 22.8% aggregate growth rate over the last seven years.
	CTIS receives the Capability Maturity Model® Integration (CMMI) Maturity Level 3 certification . The Level 3 rating indicates that CTIS' software processes are defined and institutionalized across the organization.
	CTIS attained Microsoft Gold Certified Partner status, the highest partner level program within Microsoft, for the fourth consecutive year, with a score of 150 points.
	CTIS receives the Microsoft Certified Partner award in recognition of their commitment and dedication to enable people and businesses to realize their potential with Microsoft software solutions
	As part of the Microsoft Certified Partner Program, CTIS receives Solution Competency awards in the areas of Network Infrastructure Solutions, Mobility Solutions, Information Worker Solutions and Custom Development Solutions . Organizations must attain at least two Solution Competency awards to meet Gold Certification criteria.
	CTIS receives Computerworld's Best Practice Award for Infrastructure Management in the Security, Risk Management and Business Continuity/Dynamic Information category on behalf of the work performed for the Cancer Therapy Evaluation Program (CTEP) and the National Cancer Institute (NCI).
	CTIS received the Best Practices Award from Bio-IT World

ACHIEVEMENTS

	<p>CTIS developed Cancer Therapy Evaluation Program - Enterprise System (CTEP-ESYS) was rate by the U.S. Capital Planning and Investment Control (CPIC) as number 2 out of 6 major NIH investments (214 total investments) with a CPIC score of 9.7 (out of 10). The score also places the CTEP-ESYS 4th out of the 75 major DHHS investments (651 total investments).</p>
	<p>The Cancer Therapy Evaluation Program's (CTEP) IT investment was ranked the number one priority investment. The ranking is part of the Office of Management and Budget (OMB) Exhibit 300, a capital asset plan submitted for major IT systems and IT budget initiatives at the Department Health and Human Services (DHHS). The OMB CTEP report shows an over 265% return on investment (ROI) to the government with an ROI average of over 300% for the last five years.</p>
	<p>NIH Director's Award and NCI Director's Award - CTEP Management team was awarded the NIH and NCI Director's Award in recognition for continued successful management and oversight provided for the Cancer Therapy Evaluation Program – Enterprise System (CTEP-ESYS), a Clinical Trials and Research Management (CTRM) system.</p>
	<p>CTIS received the 2010 National Institute of Allergy and Infectious Diseases (NIAID) Merit Award for the Division Of AIDS (DAIDS) Protocol Registration System for recognition of outstanding contributions and performance on the protocol registration project which resulted in improving operations critical to NIAID research.</p>
	<p>Government Performance and Results Act (GPRA) rated CTIS as exceptional (highest level) five years in a row.</p>
	<p>CancerNet™ service that CTIS operated and supported for NCI was voted as one of the world's 50 best websites by CIO Magazine.</p>
	<p>British Medical Journal voted CancerNet™ service as the world's most comprehensive source of clinical oncology trials data</p>